The seed round was led by The Discovery Lab of IBA to support product validation and laboratory expansion.
"Advanced diagnostics shouldn’t be gated by geography – the centre of gravity for precision diagnostics needs to shift. We founded Signatur to change the way molecular diagnostics are delivered. This funding brings us closer to ensuring that patients can benefit from precision testing no matter where they are. By turning complex lab processes into simple kits, we’re giving control back to hospitals across Europe and beyond. This funding is a step toward a more resilient and self-sufficient diagnostic ecosystem"
Zinc VC has led a pre-seed funding round in Native Labs to accelerate platform deployment and feature development.
"We are excited to be partnering with the Native Labs team as they build the critical infrastructure required to accelerate the development and delivery of cell therapies. Their platform is addressing one of the most challenging bottlenecks in the field, enabling more seamless, data-driven communication between developers and manufacturers. In a market that is growing rapidly, and with the potential to transform patient outcomes, Native Labs is not only solving a deeply complex technical challenge but unlocking a massive opportunity for impact across the entire cell and gene therapy ecosystem."
The financing round was co-led by RA Capital Management and Forbion to support late-stage clinical development.
"We are delighted to secure the investment required to continue to advance inobrodib fully and as effectively as possible. This is a significant raise in a challenging market. Today's announcement is a testament to the data we have in hand, the clear clinical and commercial opportunity inobrodib represents, and the strength of our expanded team."
Twin Path Ventures led the seed financing for the Belfast biotechnology firm to accelerate its preclinical discovery programmes.
"Ten years ago, I began combining financial modeling expertise with computational biology to create a drug discovery platform. Evolution has spent billions of years perfecting natural defense mechanisms, and now we’re using AI to unlock this wisdom. This isn’t just professional for me; my father died from a drug-resistant infection our healthcare system couldn’t treat. At Queen’s, I built AMPLY to tackle deadly diseases differently, creating technology that will save lives when current treatments fail."
